Cytoplasmic RAP1 mediates cisplatin resistance of non-small cell lung cancer

Cytotoxic chemotherapy agents (e.g., cisplatin) are the first-line drugs to treat non-small cell lung cancer (NSCLC) but NSCLC develops resistance to the agent, limiting therapeutic efficacy. Despite many approaches to identifying the underlying mechanism for cisplatin resistance, there remains a la...

Descripción completa

Detalles Bibliográficos
Autores principales: Xiao, Lu, Lan, Xiaoying, Shi, Xianping, Zhao, Kai, Wang, Dongrui, Wang, Xuejun, Li, Faqian, Huang, Hongbiao, Liu, Jinbao
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group 2017
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5520727/
https://www.ncbi.nlm.nih.gov/pubmed/28518145
http://dx.doi.org/10.1038/cddis.2017.210

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5520727/
https://www.ncbi.nlm.nih.gov/pubmed/28518145
http://dx.doi.org/10.1038/cddis.2017.210

Ejemplares similares